drugset / Trial / NCT02930109
A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
NaSingle-groupOpen-labelTreatment
Summary
A phase I-II open label study of PTX-200 in combination with cytarabine in the treatment of relapsed or refractory acute leukemia.
Timeline
- Start
- 2016-12-09
- Primary completion
- 2023-10-31
- Completion
- 2024-03-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PTX-200 | Unknown | 25 mg/m2 | Intravenous |
| Subject | PTX-200 | Unknown | 35 mg/m2 | Intravenous |
| Subject | PTX-200 | Unknown | 45 mg/m2 | Intravenous |
| Subject | PTX-200 | Unknown | 55 mg/m2 | Intravenous |
| Background | Cytarabine | Small molecule | 400 mg/m2 | Intravenous |